What is DFTX's current stock price?

DFTX (Definium Therapeutics, Inc.) is currently trading at $22.50 with a market cap of $2.45B.

What sector is Definium Therapeutics, Inc. in?

Definium Therapeutics, Inc. (DFTX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is DFTX a good stock to buy?

Analysts have a Buy consensus on DFTX with a price target of $35.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

DFTX Definium Therapeutics, Inc.

Healthcare

$22.50-0.66%ClosedMarket Cap: $2.45B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

8.78

P/S

0.00

EV/EBITDA

-10.62

DCF Value

$2.83

FCF Yield

-5.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-102.5%

ROA

-59.2%

ROIC

-60.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-77.1M	$—
Q4 null	$0.00	$-50.4M	$—
FY null	$0.00	$-183.8M	$—
Q3 null	$0.00	$-67.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$35.50

Target (Median)

$36.50

Target Range

$25.00 - $48.00

4 Strong Buy12 Buy0 Hold0 Sell0 Strong Sell

Piper SandlerOverweight

2026-05-08

Leerink PartnersOutperform

2026-04-22

Canaccord GenuityBuy

2026-04-16

HC Wainwright & Co.Buy

2026-03-02

RBC CapitalOutperform

2026-01-23

Trading Activity

Insider Trades

View All

Sullivan Markofficer: Chief Legal Officer

SellThu Mar 26

Karlin Danielofficer: Chief Medical Officer

SellThu Mar 26

Barrow Robertdirector, officer: Chief Executive Officer

SellThu Mar 26

Wiley Matthew T.officer: Chief Commercial Officer

SellThu Feb 05

Sullivan Markofficer: Chief Legal Officer

SellThu Feb 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.38

Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Peers

KOD